Nachrichten zur AstraZeneca PLC Aktie

Citi sees Daiichi supply review as immaterial for AstraZeneca

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyos decision…

Saphnelo self-administration approved in the US

27 April 2026Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosusFirst-in-class Saphnelo Pen now…

Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights

Astrazeneca (AZN) concluded the recent trading session at $192.3, signifying a -1.29% move from its prior days close.…

AstraZenecas Ultomiris Meets Goal in Rare Kidney Disease Study

AZNs Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major markets.…

AstraZenecas tozorakimab treble puts $5bn sales ceiling in sight, says Citi

A third consecutive phase III success for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) tozorakimab in chronic obstructive pulmonary disease (COPD) has reinforced...…

AstraZenecas Ultomiris hits primary endpoint in rare kidney disease trial

AstraZeneca PLCs (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN),…

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Astrazeneca (AZN) reached $201.21 at the closing of the latest trading day, reflecting a -1.55% change compared to its last…

AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside

UBS and Citi both maintain buy ratings on the Anglo-Swedish drugmaker ahead of its first-quarter results, with a rich pipeline…

Result of AGM

9 April 2026Results of Annual General Meeting held on 9 April 2026AstraZeneca PLC announced the results of the voting at…

AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?

Though both dominate oncology, a stronger growth outlook and clearer targets may give AstraZeneca an edge over Merck.…

The Zacks Analyst Blog Highlights AstraZeneca, HSBC, Walt Disney, Oak Valley Bancorp and BV Financial

AstraZeneca (AZN) leads Zacks Research highlights with strong drug growth and pipeline momentum, while HSBC and Disney navigate costs and…

AstraZeneca Aktie: "Top Pick" mit neuem Rückenwind!

New York (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von Morgan Stanley:Morgan Stanley habe das Kursziel für die Aktie von AstraZeneca plc (ISIN: GB0009895292,…

Top Research Reports for AstraZeneca, HSBC & Walt Disney

AstraZenecas strong drug portfolio and pipeline fuel growth targets, while HSBC restructures and Disney balances streaming gains against rising costs.…

AstraZenecas liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug

A positive phase three trial result in a hard-to-treat cancer adds fresh momentum to one of AstraZenecas most important growth…

AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns

…

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Astrazeneca (AZN) concluded the recent trading session at $203.49, signifying a +1.37% move from its prior days close.…

US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported mixed phase three trial data for efzimfotase alfa, its treatment for hypophosphatasia, a rare…

Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPDs hardest-to-treat patients

Fridays positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), arriving at a moment…

Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors

In the latest trading session, Astrazeneca (AZN) closed at $188.42, marking a +2.74% move from the previous day.…

AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.…

Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more

These are the stocks posting the largest moves premarket.…

AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard…

AstraZeneca shares rise to top of FTSE 100 as COPD drug clears two pivotal trials

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares rose 3% to 14,230p, placing the drugmaker at the top of the FTSE 100 leaderboard…

Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know

The latest trading day saw Astrazeneca (AZN) settling at $183.6, representing a -2.82% change from its previous close.…

AstraZenecas Imfinzi Secures Approval for Gastric Cancer in the EU

AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding…

Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know

Astrazeneca (AZN) concluded the recent trading session at $189.9, signifying a -1.35% move from its prior days close.…

Mineralys (MLYS) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEThursday, March 12, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Jon CongletonChief Financial Officer…

ROUNDUP: Teilerfolg für Klage gegen Astrazeneca nach Corona-Impfung

KARLSRUHE (dpa-AFX) - Während der Corona-Pandemie wurden in Deutschland fast 200 Millionen Schutzimpfungen gegen das Virus…

Teilerfolg für Klage gegen AstraZeneca im Prozess um Impfschaden

Sie erhält eine Covid-Impfung und erleidet einen Hörsturz. Nun hat die Frau den Rechtsstreit mit dem Impfstoffhersteller AstraZeneca vor den…

Klage gegen AstraZeneca: Wann Impfstoffhersteller haften

Vor dem Bundesgerichtshof geht es heute um mögliche Ansprüche nach einer Corona-Impfung. Eine Klägerin verlangt Schadensersatz und Auskunft vom Hersteller…

ROUNDUP/Klage gegen Astrazeneca: Wann haften Impfstoffhersteller?

KARLSRUHE (dpa-AFX) - Im Laufe der Corona-Pandemie wurden in Deutschland fast 200 Millionen Impfungen zum Schutz…

Bundesgerichtshof entscheidet zu Impfschaden-Klage

KARLSRUHE (dpa-AFX) - Der Bundesgerichtshof (BGH) entscheidet am Montag (11 Uhr) über eine Klage gegen den…

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial

Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has…

The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop

Exxon Mobil, Palantir and AstraZeneca lead Zacks latest analyst reports, highlighting strong production growth, AI momentum and a robust drug…

Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca

Exxon Mobil leads fresh analyst reports as Permian and Guyana output power growth, while Palantirs AI platforms and AstraZenecas drug…

SOPHiA GENETICS (SOPH) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DATEMarch 3, 2026, 8 a.m. ETCALL PARTICIPANTSChief Executive Officer — Jurgi CamblongChief Financial Officer — George…

Salesforce CEO touts company resilience amid software slump

Looking back, it almost seems like a dream. On Aug. 31, 2020, the U.S. had just surpassed six million COVID-19…

LNTH: 2025 Earnings Flash Report

By John Vandermosten, CFANASDAQ:LNTHLantheus Reports 2025 Financial and Operational Results Lantheus Holdings, Inc. (NASDAQ:LNTH) reported financial results yesterday. Revenue was…

AstraZeneca has sector leading replacement power to cope with 2030 patent cliff

The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS,...…

Arcus (RCUS) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEWednesday, Feb. 25, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Terry J. RosenPresident —…

IonQ (IONQ) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DateFeb. 25, 2026 at 4:30 p.m. ETCall participantsChairman and Chief Executive Officer — Niccolo de MasiChief…

AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?

AZNs stronger growth outlook and 2030 revenue target may outshine PFEs yield and cheaper valuation.…

Fixed-duration Calquence combo approved in US

20 February 2026Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in…

Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor

In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…

Inside Biotech: AstraZeneca halts generic diabetes pill launch in patent battle with Pharmacor

In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal…

Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer

Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed…

Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus

…

Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory

Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to hold from buy, citing a less favourable earnings trajectory as the drugmaker...…

KORREKTUR/ROUNDUP: Astrazeneca will 2026 mehr verdienen - Aktie nahe Rekordhoch

(Es wird in der Überschrift und im 1. Absatz klargestellt, dass die Aktie sich ihrem Rekordhoch…